<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00980876</url>
  </required_header>
  <id_info>
    <org_study_id>STPh 09/08</org_study_id>
    <nct_id>NCT00980876</nct_id>
  </id_info>
  <brief_title>A Comparative Study Between Two Formulations of the Ciprofloxacin Hydrochloride + Hydrocortisone Otic Suspension</brief_title>
  <official_title>Multicentric, Double Blind, Randomized, Parallel Comparative Study Between Ciprofloxacin HCl 2 mg/mL + Hydrocortisone 10 mg/mL Ear Suspension and Cipro HC®, for the Assessment of Efficacy and Safety in Patients With Otitis Externa.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Farmoquimica S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmagenix Projetos em Medicina Farmacêutica Ltda.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Farmoquimica S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the efficacy and safety profiles of the test
      product containing 2 mg/mL ciprofloxacin hydrochloride associated with 10 mg/mL of
      hydrocortisone with the reference product Cipro HC®, in patients with acute otitis externa.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase III, non inferiority, multicentric, controlled, single blind, parallel-group,
      randomized study.

      Population: 224 patients with external otitis , men and women aged between 1 - 70 years.

      Primary endpoint: The primary endpoint of this study is the elimination of pain, swelling and
      otorrhea (cure).

      Secondary endpoint: The endpoint will be the identification of the side effects of medication
      use.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cure (reduced pain, swelling and otorrhea)</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of possible side effects</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">224</enrollment>
  <condition>Otitis Externa</condition>
  <arm_group>
    <arm_group_label>Cipro HC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reference product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ciprofloxacin HCl and Hydrocortisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test product</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cipro HC</intervention_name>
    <description>Cipro HC (Ciprofloxacin HCl and Hydrocortisone)</description>
    <arm_group_label>Cipro HC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin HCl and Hydrocortisone</intervention_name>
    <description>Ciprofloxacin Hydrochloride and Hydrocortisone</description>
    <arm_group_label>Ciprofloxacin HCl and Hydrocortisone</arm_group_label>
    <other_name>Otociriax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed of the nature of the study and given written informed consent;

          -  Patients with acute otitis externa;

          -  Intact tympanic membrane.

        Exclusion Criteria:

          -  Known allergy or sensitivity to Ciprofloxacin Hydrochloride and Hydrocortisone;

          -  Patient has the tympanic membrane not intact;

          -  Diabetes

          -  Bilateral Acute Otitis Externa;

          -  Pregnant or lactating patients;

          -  Overt fungal Acute Otitis Externa;

          -  Other diseases of the ear

          -  Current Infection requiring systemic antimicrobial therapy.

          -  Current enrollment in an investigational drug or device study or participation in such
             a study within 30 days of entry into this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agricio N. Crespo, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clínica Quiron</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clínica Quiron</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <zip>13087-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2009</study_first_submitted>
  <study_first_submitted_qc>September 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2009</study_first_posted>
  <last_update_submitted>April 16, 2015</last_update_submitted>
  <last_update_submitted_qc>April 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Otitis</mesh_term>
    <mesh_term>Otitis Externa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Ciprofloxacin, hydrocortisone drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

